Document is current
Any future updates will be listed below
-
Authors
Mørk, Sofie Kirial https://orcid.org/0009-0000-1119-0047
Skadborg, Signe Koggersbøl
Albieri, Benedetta
Draghi, Arianna https://orcid.org/0000-0002-5894-6750
Bol, Kalijn https://orcid.org/0000-0003-4165-2040
Kadivar, Mohammad
Westergaard, Marie Christine Wulff
Stoltenborg Granhøj, Joachim
Borch, Annie
Petersen, Nadia Viborg
Thuesen, Nikolas
Rasmussen, Ida Svahn
Andreasen, Lars Vibe
Dohn, Rebecca Bach
Yde, Christina Westmose
Noergaard, Nis
Lorentzen, Torben
Soerensen, Anders Bundgaard
Kleine-Kohlbrecher, Daniela
Jespersen, Anders
Christensen, Dennis
Kringelum, Jens
Donia, Marco https://orcid.org/0000-0003-4966-9752
Hadrup, Sine Reker https://orcid.org/0000-0002-5937-4344
Marie Svane, Inge
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03715985 at ClinicalTrials.govnct03715985 at ClinicalTrials.govDocuments that mention this clinical trial
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma
https://doi.org/10.1136/jitc-2024-008817
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9551
Documents that mention this clinical trial
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma
https://doi.org/10.1136/jitc-2024-008817
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9551
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R246-A14741-19-S73)
Innovationsfonden (7051-00010B)
- License Information
